Table 2.
Variable |
DCE-MRI subjectsa |
P-value | |
---|---|---|---|
Included (N=98) | Excluded (N=108) | ||
Sex – no. (%) | 0.46 | ||
Male | 84 (86%) | 88 (81%) | |
Female | 14 (14%) | 20 (19%) | |
Age – years | 62±9 | 61±8 | 0.30 |
Raceb – no. (%) | 0.026 | ||
White | 90 (92%) | 86 (80%) | |
Non-white/other | 8 (8%) | 21 (20%) | |
Ethnicityb – no. (%) | 0.38 | ||
Hispanic or Latino | 4 (4%) | 8 (7%) | |
Not Hispanic or Latino | 93 (96%) | 100 (93%) | |
Tobacco use – no. (%) | 0.48 | ||
Current | 21 (21%) | 17 (16%) | |
Former (quit>1 year ago) | 48 (49%) | 61 (56%) | |
Never used | 29 (30%) | 30 (28%) | |
Duration of statin therapy – no. (%) | 0.76 | ||
<1 year | 21 (21%) | 28 (26%) | |
1–5 years | 39 (40%) | 40 (37%) | |
>5 years | 38 (39%) | 40 (37%) | |
Prior use of niacin – no. (%) | 15 (15%) | 22 (20%) | 0.37 |
Presence of metabolic syndrome – no. (%) | 79 (81%) | 87 (81%) | >0.99 |
History of diabetes – no. (%) | 22 (22%) | 32 (30%) | 0.27 |
Body mass indexb – kg / m2 | 29.7±4.1 | 30.9±4.8 | 0.064 |
Systolic blood pressureb – mmHg | 129±18 | 128±17 | 0.87 |
Diastolic blood pressureb – mmHg | 75±10 | 75±9 | 0.72 |
Total cholesterol – mg/dl | 139±23 | 141±28 | 0.92 |
LDL cholesterol – mg/dl | 71±18 | 73±25 | 0.91 |
Non-HDL cholesterol – mg/dl | 105±21 | 107±28 | 0.88 |
Triglycerides – mg/dl | 169±62 | 171±63 | 0.78 |
Lipoprotein(a)b – mg/dl | 83.6±89.8 | 73.5±92.0 | 0.41 |
ApoBb – mg/dl | 82.2±19.0 | 82.5±21.4 | 0.97 |
HDL cholesterol – mg/dl | 34.3±6.1 | 34.9±5.2 | 0.62 |
ApoA-Ib – mg/dl | 118.9±16.4 | 123.9±16.7 | 0.10 |
Total:HDL ratio | 4.2±0.8 | 4.1±1.1 | 0.67 |
ApoB:ApoA-I ratiob | 0.7±0.2 | 0.7±0.2 | 0.29 |
Unless otherwise specified, values are no. (%) or means±SD.
Only includes those already on statins at enrollment with known prior duration.
Individuals missing values excluded for comparisons involving that variable, including: race (n=1), ethnicity (n=1), body mass index (n=1), systolic blood pressure (n=1), diastolic blood pressure (n=1), lipoprotein(a) (n=2), apoB (n=2), apoA-I (n=2) and apoB: apoA-I ratio (n=2).